MAE方案联合化疗治疗CD_7^+急性髓性白血病疗效观察  

Clinical observation of chemotherapy with MAE protocol for CD_7 positive acute myelogenous leukemia

作　　者：赵晓武[1] 彭晓景[1] 符粤文[1] 董秀娟[1] 马红霞[1] 赛亚[1] 刘文刚[1] 侯天德[1] 

机构地区：[1]郑州市第三人民医院血液科,郑州450000

出　　处：《临床血液学杂志》2001年第1期21-23,共3页Journal of Clinical Hematology

摘　　要：目的 :探讨应用米托蒽醌 +阿糖胞苷 +足叶乙甙 (MAE)方案治疗 CD7+急性髓性白血病 (CD7+AML)的有效性。方法 :采用 MAE方案联合化疗治疗经细胞形态学、细胞化学及细胞免疫学分型诊断为 CD7+AML 1 2例 ,并监测化疗后骨髓像变化及化疗相关毒性反应。结果 :1 2例中 , 7例达完全缓解 , 1例达部分缓解 ,总有效率为 66. 7%,持续缓解时间 6～ 3 6个月。化疗相关毒性略大于 HA和 DA方案 ,主要特征为骨髓抑制期延长。结论 :MAE方案可提高 CD7+AML的缓解率 ,尽管化疗后骨髓抑制期延长 。Objective:To study the effect of chemotherapy with MAE protocol for CD 7 positive acute myelogenous leukemia (CD 7 +AML) which represented a distinct biological and clinical subtype.Methods:Immunophenotyping in 97 patients of AML was tested by indirect immunofluorescence. Patients of CD 7 positive expression received the treatment with MIT,Ara c,Vp 16. The change of bone marrow and peripheral blood cell after chemotherapy and the clinical feature of related toxicity were monitored.Results:CD 7 + was expressed in 12 patients ( 12.6 %). Of the 12 patients, 7 cases achieved complete remission (CR), 1 case partial remission (PR), the overall response rate was approximately 66.7 %, and DFS were 6～36 months. The chemotherapy related toxicity was slightly bigger than that of HA,DA protocol and the salient clinical features was the prolongation of the arrest interval of bone marrow.Conclusions:MAE protocol could improved CR rate in CD 7 +AML, bone marrow hemotopoietic impression was prolonged but no lethal complication existed.

关 键 词：化学疗法 血液疾病 急性白血病 治疗 

分 类 号：R733.710.5[医药卫生—肿瘤]